Bulk and single-cell RNA sequencing data identified HMGB3 of chromatin regulators as a breast cancer biomarker associated with the cell cycle - Report - MDSpire
Advertisement
Bulk and single-cell RNA sequencing data identified HMGB3 of chromatin regulators as a breast cancer biomarker associated with the cell cycle
Clinical Report: Identification of HMGB3 as a Breast Cancer Biomarker
Overview
This study identifies HMGB3 as a novel biomarker linked to breast cancer (BRCA) progression through its role in the cell cycle. The research demonstrates that high HMGB3 expression correlates with poor overall survival and increased immune cell infiltration in BRCA patients.
Background
Breast cancer is a leading cause of cancer-related deaths among women globally, with significant increases in incidence projected. Identifying early biomarkers is crucial for improving prognostic predictions and treatment strategies. Chromatin regulators, such as HMGB3, are implicated in tumorigenesis and may influence the tumor microenvironment.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
Eleven chromatin regulators were identified and used to create a prognostic model for BRCA.
Patients were categorized into high- and low-risk groups based on median risk scores.
HMGB3 expression levels were closely associated with BRCA progression.
In vitro assays indicated that HMGB3 enhances BRCA cell invasion and promotes malignant progression.
Clinical Implications
The identification of HMGB3 as a biomarker may aid in stratifying BRCA patients based on risk and could inform therapeutic decisions. Further studies are warranted to explore HMGB3's potential as a target for intervention in BRCA.
Conclusion
HMGB3 emerges as a significant biomarker in breast cancer, linking chromatin regulation to tumor progression and immune response. Continued investigation into its role may enhance prognostic accuracy and therapeutic strategies.
